Завод ДИОД DIOD

Завод ДИОД Balance Sheet 2007-2026 | DIOD

Annual Balance Sheet Завод ДИОД

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash And Cash Equivalents	34.1 M	108 M	88.6 M	49.8 M	4.02 M	30.4 M	7.7 M	10.7 M	144 M	1.8 M	14.1 M	17.3 M	17.3 M	38 M	38.5 M	28.6 M	23.1 M
Total Current Assets	874 M	933 M	936 M	921 M	914 M	918 M	923 M	1.01 B	1.16 B	1.33 B	1.66 B	1.8 B	1.66 B	1.43 B	1.24 B	1.12 B	908 M
Property Plant Equipment Net	250 M	260 M	271 M	268 M	276 M	248 M	265 M	270 M	282 M	293 M	304 M	318 M	489 M	452 M	443 M	401 M	384 M
Intangible Assets	165 M	167 M	162 M	161 M	85.6 M	90.9 M	348 M	346 M	443 M	544 M	461 M	473 M	-	-	-	-	3.51 M
Goodwill And Intangible Assets	195 M	197 M	192 M	191 M	116 M	121 M	378 M	376 M	525 M	840 M	727 M	739 M	1.43 B	1.43 B	1.37 B	744 M	218 M
Long-Term Investments	4 K	-102 M	-	-	126 M	12.9 M	29.1 M	-	26.9 M	-	-	-	-	-	-	-	25.1 M
Tax Assets	-	27.1 M	22.9 M	16.9 M	18.3 M	19.1 M	38.6 M	25.7 M	43.5 M	33 M	34.9 M	36.7 M	45.5 M	50.9 M	45.8 M	33.4 M	28.8 M
Total Non Current Assets	473 M	484 M	477 M	477 M	535 M	510 M	711 M	672 M	877 M	1.19 B	1.09 B	1.33 B	1.96 B	1.93 B	1.86 B	1.23 B	667 M
Total Assets	1.35 B	1.42 B	1.42 B	1.4 B	1.45 B	1.43 B	1.63 B	1.68 B	2.04 B	2.53 B	2.75 B	3.12 B	3.62 B	3.36 B	3.1 B	2.35 B	1.57 B
Account Payables	15 M	14 M	31.3 M	75.9 M	116 M	83.9 M	112 M	51.9 M	105 M	113 M	60.9 M	432 K	95.8 M	36.1 M	44.8 M	48.2 M	21.1 M
Short-Term Debt	-	-	4.26 M	1.24 M	8.04 M	3.32 M	-18.1 M	10 M	15.2 M	446 M	483 M	227 M	284 M	234 M	453 M	206 M	182 M
Tax Payables	-	117 K	686 K	651 K	2.88 M	32.7 M	36.4 M	48.6 M	61.8 M	44.1 M	22.1 M	23.5 M	81.7 M	51.5 M	61.8 M	74.3 M	47.7 M
Deferred Revenue	-	-	9.65 M	14 M	8.76 M	20.7 M	17.4 M	76.2 M	-	-	-	96.4 M	-	-	-	-	-
Total Current Liabilities	130 M	123 M	102 M	105 M	159 M	183 M	187 M	177 M	374 M	732 M	680 M	478 M	565 M	491 M	718 M	459 M	402 M
Long-Term Debt	-	-	-	-	34.1 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	340 M	711 M	460 M	381 M	76.4 M	310 M	-
Deferred Revenue Non Current	-	-	-42.8 M	-42.8 K	-34.1 K	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities Non Current	-	51.1 M	49.2 M	46.7 M	47.1 M	60.4 M	90.6 M	92.9 M	113 M	122 M	122 M	128 M	283 M	295 M	281 M	152 M	73.1 M
Total Non Current Liabilities	90.4 M	93.7 M	92 M	89.5 M	81.1 M	67.8 M	98 M	100 M	121 M	130 M	462 M	839 M	749 M	691 M	379 M	462 M	73.1 M
Total Liabilities	220 M	217 M	194 M	195 M	240 M	251 M	285 M	277 M	494 M	862 M	1.14 B	1.32 B	1.31 B	1.18 B	1.1 B	922 M	475 M
Retained Earnings	1.15 B	1.21 B	1.24 B	1.21 B	1.22 B	1.18 B	1.35 B	1.42 B	1.56 B	1.68 B	1.63 B	1.82 B	1.85 B	1.82 B	1.71 B	1.37 B	808 M
Accumulated Other Comprehensive Income Loss	1 K	-0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	280 M
Total Stockholders Equity	1.13 B	1.21 B	1.24 B	1.21 B	1.21 B	1.18 B	1.35 B	1.42 B	1.56 B	1.68 B	1.62 B	1.82 B	1.85 B	1.82 B	1.71 B	1.37 B	1.09 B
Total Liabilities And Stockholders Equity	1.35 B	1.42 B	1.42 B	1.4 B	1.45 B	1.43 B	1.63 B	1.68 B	2.04 B	2.53 B	2.75 B	3.12 B	3.62 B	3.36 B	3.1 B	2.35 B	1.57 B
Total Investments	4 K	4 K	88.4 M	78 M	26.6 M	84.9 M	75.7 M	80 M	26.9 M	28.2 M	26.5 M	231 M	111 K	156 K	943 K	19.1 M	25.1 M
Total Debt	-	-	47 M	1.24 M	8.04 M	71.5 M	55.4 M	17.5 M	22.6 M	454 M	822 M	938 M	744 M	615 M	529 M	516 M	182 M
Net Debt	-34.1 M	-108 M	-41.5 M	-48.6 M	4.01 M	41.1 M	47.7 M	6.8 M	-121 M	452 M	808 M	921 M	726 M	577 M	491 M	488 M	159 M

All numbers in RUB currency

Quarterly Balance Sheet Завод ДИОД

	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Cash And Cash Equivalents	124 M	108 M	144 M	88.6 M	108 M	49.8 M	33.6 M	4.02 M	54.6 M	30.4 M	18.7 M	7.7 M	14.1 M	10.7 M	46.4 M	144 M	4.2 M	1.8 M	14.7 M	14.1 M	20.8 M	17.3 M	27.6 M	38 M	38.2 M	38.5 M	33.5 M	28.6 M	25.9 M
Total Current Assets	962 M	933 M	956 M	936 M	982 M	921 M	949 M	914 M	935 M	918 M	955 M	923 M	1.07 B	1.01 B	1.36 B	1.16 B	1.2 B	1.33 B	1.42 B	1.66 B	1.71 B	1.66 B	1.54 B	1.43 B	1.33 B	1.24 B	1.18 B	1.12 B	1.01 B
Property Plant Equipment Net	256 M	260 M	262 M	271 M	268 M	268 M	272 M	276 M	258 M	248 M	259 M	265 M	266 M	270 M	277 M	282 M	287 M	293 M	299 M	304 M	310 M	489 M	471 M	452 M	448 M	443 M	422 M	401 M	393 M
Intangible Assets	164 M	167 M	161 M	162 M	165 M	161 M	81 M	85.6 M	99.3 M	90.9 M	324 M	348 M	361 M	346 M	333 M	443 M	534 M	544 M	523 M	461 M	465 M	-	-	-	-	-	-	-	1.75 M
Goodwill And Intangible Assets	194 M	197 M	191 M	192 M	195 M	191 M	111 M	116 M	129 M	121 M	354 M	378 M	391 M	376 M	363 M	525 M	830 M	840 M	789 M	727 M	731 M	1.43 B	1.43 B	1.43 B	1.4 B	1.37 B	1.06 B	744 M	481 M
Long-Term Investments	-107 M	-102 M	-	-	-	-	-	126 M	106 M	12.9 M	-	-	-	-	-	26.9 M	-	-	-	-	26.5 M	-	-	-	-	-	-	-	12.6 M
Tax Assets	26.2 M	27.1 M	29.3 M	22.9 M	14.6 M	16.9 M	-	18.3 M	16.1 M	19.1 M	37 M	38.6 M	27.6 M	25.7 M	46.1 M	43.5 M	-	33 M	54.5 M	34.9 M	33 M	45.5 M	48.2 M	50.9 M	48.3 M	45.8 M	39.6 M	33.4 M	31.1 M
Total Non Current Assets	476 M	484 M	482 M	477 M	477 M	477 M	493 M	535 M	509 M	510 M	683 M	711 M	684 M	672 M	715 M	877 M	1.19 B	1.19 B	1.2 B	1.09 B	1.1 B	1.96 B	1.95 B	1.93 B	1.9 B	1.86 B	1.54 B	1.23 B	947 M
Total Assets	1.44 B	1.42 B	1.44 B	1.42 B	1.46 B	1.4 B	1.44 B	1.45 B	1.44 B	1.43 B	1.64 B	1.63 B	1.75 B	1.68 B	2.08 B	2.04 B	2.39 B	2.53 B	2.62 B	2.75 B	2.81 B	3.62 B	3.49 B	3.36 B	3.23 B	3.1 B	2.72 B	2.35 B	1.96 B
Account Payables	53.7 M	14 M	17.8 M	31.3 M	13.8 M	75.9 M	64.4 M	116 M	28.4 M	83.9 M	26.7 M	112 M	72.8 M	51.9 M	329 M	105 M	130 M	113 M	84.2 M	60.9 M	91 M	95.8 M	66 M	36.1 M	40.5 M	44.8 M	46.5 M	48.2 M	34.6 M
Short-Term Debt	-	-	-	4.26 M	-	1.24 M	8.3 M	8.04 M	30.4 M	3.32 M	59 M	-18.1 M	32.7 M	10 M	9.73 M	15.2 M	399 M	446 M	520 M	483 M	413 M	284 M	259 M	234 M	343 M	453 M	330 M	206 M	194 M
Tax Payables	179 K	117 K	570 K	686 K	317 K	651 K	-	2.88 M	21.5 M	32.7 M	24.2 M	36.4 M	49.7 M	48.6 M	46.7 M	61.8 M	-	44.1 M	39.6 M	22.1 M	23.5 M	81.7 M	66.6 M	51.5 M	56.6 M	61.8 M	68.1 M	74.3 M	61 M
Deferred Revenue	-	-	-828	9.65 M	28.7 M	-	-	8.76 M	120 M	20.7 M	-	-	112 M	76.2 M	-	-	-	-	116 M	-	23.5 M	-	-	-	-	-	-	-	-
Total Current Liabilities	192 M	123 M	171 M	102 M	168 M	105 M	145 M	159 M	179 M	183 M	211 M	187 M	255 M	177 M	535 M	374 M	638 M	732 M	756 M	680 M	559 M	565 M	528 M	491 M	604 M	718 M	589 M	459 M	431 M
Long-Term Debt	-	-	-	42.8 M	-	-	34 M	34.1 M	7.63 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	7.45 M	105 M	340 M	496 M	460 M	421 M	381 M	229 M	76.4 M	193 M	310 M	155 M
Deferred Revenue Non Current	-	-	-40.9 K	-42.8 M	-	-	-	-34.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities Non Current	49 M	51.1 M	51.7 M	49.2 M	44.9 M	46.7 M	-	47.1 M	40.8 M	60.4 M	91.1 M	90.6 M	91.9 M	92.9 M	96.2 M	113 M	119 M	122 M	137 M	122 M	125 M	283 M	289 M	295 M	288 M	281 M	217 M	152 M	113 M
Total Non Current Liabilities	92.3 M	93.7 M	92.6 M	92 M	87.6 M	89.5 M	80.5 M	81.1 M	74.9 M	67.8 M	98.5 M	98 M	99.3 M	100 M	104 M	121 M	126 M	130 M	242 M	462 M	621 M	749 M	720 M	691 M	535 M	379 M	420 M	462 M	268 M
Total Liabilities	285 M	217 M	264 M	194 M	256 M	195 M	226 M	240 M	254 M	251 M	310 M	285 M	354 M	277 M	638 M	494 M	764 M	862 M	999 M	1.14 B	1.18 B	1.31 B	1.25 B	1.18 B	1.14 B	1.1 B	1.01 B	922 M	698 M
Retained Earnings	1.17 B	1.21 B	1.19 B	1.24 B	1.22 B	1.21 B	1.22 B	1.22 B	1.2 B	1.18 B	1.33 B	1.35 B	1.41 B	1.42 B	1.46 B	1.56 B	1.36 B	1.68 B	1.64 B	1.63 B	1.65 B	1.85 B	1.84 B	1.82 B	1.77 B	1.71 B	1.54 B	1.37 B	1.09 B
Accumulated Other Comprehensive Income Loss	-	-0.0	-0.0	-	-	-	0.0	-	-	-	-	-	-	-	-	-	279 M	-	-	-	-	-	-	-	-	-	-	-	140 M
Total Stockholders Equity	1.15 B	1.21 B	1.18 B	1.24 B	1.21 B	1.21 B	1.22 B	1.21 B	1.19 B	1.18 B	1.33 B	1.35 B	1.41 B	1.42 B	1.45 B	1.56 B	1.64 B	1.68 B	1.64 B	1.62 B	1.65 B	1.85 B	1.84 B	1.82 B	1.77 B	1.71 B	1.54 B	1.37 B	1.23 B
Total Liabilities And Stockholders Equity	1.44 B	1.42 B	1.44 B	1.42 B	1.46 B	1.4 B	1.44 B	1.45 B	1.44 B	1.43 B	1.64 B	1.63 B	1.75 B	1.68 B	2.08 B	2.04 B	2.39 B	2.53 B	2.62 B	2.75 B	2.81 B	3.62 B	3.49 B	3.36 B	3.23 B	3.1 B	2.72 B	2.35 B	1.96 B
Total Investments	4 K	4 K	99.3 M	88.4 M	85.8 M	78 M	28.9 M	26.6 M	72 M	84.9 M	75.7 M	75.7 M	80 M	80 M	80 M	26.9 M	-	28.2 M	56.5 M	26.5 M	26.5 M	111 K	134 K	156 K	550 K	943 K	10 M	19.1 M	22.1 M
Total Debt	-	-	41.7 K	47 M	-	1.24 M	42.3 M	8.04 M	38 M	71.5 M	66.4 M	55.4 M	40.1 M	17.5 M	17.2 M	22.6 M	406 M	454 M	625 M	822 M	909 M	744 M	679 M	615 M	572 M	529 M	523 M	516 M	349 M
Net Debt	-124 M	-108 M	-144 M	-41.5 M	-108 M	-48.6 M	8.7 M	4.01 M	-16.5 M	41.1 M	47.7 M	47.7 M	26 M	6.8 M	-29.2 M	-121 M	402 M	452 M	610 M	808 M	888 M	726 M	652 M	577 M	534 M	491 M	489 M	488 M	323 M

All numbers in RUB currency

Balance Sheet is a fundamental financial report of Завод ДИОД, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis

Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability.
Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	$ 3.55	-0.28 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Adagene ADAG	$ 3.91	-2.01 %	$ 220 M	China
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
AC Immune SA ACIU	$ 3.32	6.07 %	$ 229 M	Schweiz
I-Mab IMAB	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	-	10.36 %	$ 9.8 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	$ 4.11	-2.61 %	$ 105 M	Schweiz
Aptorum Group Limited APM	$ 0.79	0.04 %	$ 4.31 M	China
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Arcturus Therapeutics Holdings ARCT	$ 6.39	-3.62 %	$ 175 M	Israel
Adverum Biotechnologies ADVM	-	-	$ 86.2 M	USA
argenx SE ARGX	$ 706.03	0.39 %	$ 25 B	Niderland
Alterity Therapeutics Limited ATHE	$ 3.34	-7.48 %	$ 8.04 B	Australia
Ascendis Pharma A/S ASND	$ 228.06	-1.28 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
BioCardia BCDA	$ 1.28	0.79 %	$ 27.1 M	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Atea Pharmaceuticals AVIR	$ 6.13	1.32 %	$ 500 M	USA
Институт стволовых клеток человека ISKJ	-	-	-	Russia
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
Athersys ATHX	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
Can-Fite BioPharma Ltd. CANF	$ 3.43	-4.19 %	$ 7.46 B	Israel
Allena Pharmaceuticals ALNA	-	3.16 %	$ 1.9 M	USA
Catalyst Biosciences CBIO	$ 11.1	-4.15 %	$ 992 M	USA
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Anika Therapeutics ANIK	$ 14.51	1.04 %	$ 213 M	USA
Aptinyx APTX	-	-39.0 %	$ 4.57 M	USA
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada
CNS Pharmaceuticals CNSP	$ 2.26	-7.76 %	$ 864 K	USA
AVEO Pharmaceuticals AVEO	-	-	$ 521 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.59	-1.89 %	$ 16.3 M	USA
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	$ 1.51	-	$ 385 M	Britain
BioNTech SE BNTX	$ 94.86	4.77 %	$ 27.2 B	Germany
Athira Pharma ATHA	-	-	$ 269 M	USA
CureVac N.V. CVAC	-	-	$ 867 M	Germany

Завод ДИОД Balance Sheet 2007-2026 | DIOD

Annual Balance Sheet Завод ДИОД

Cash And Cash Equivalents

Total Current Assets

Property Plant Equipment Net

Intangible Assets

Goodwill And Intangible Assets

Long-Term Investments

Tax Assets

Total Non Current Assets

Total Assets

Account Payables

Short-Term Debt

Tax Payables

Deferred Revenue

Total Current Liabilities

Long-Term Debt

Deferred Revenue Non Current

Deferred Tax Liabilities Non Current

Total Non Current Liabilities

Total Liabilities

Retained Earnings

Accumulated Other Comprehensive Income Loss

Total Stockholders Equity

Total Liabilities And Stockholders Equity

Total Investments

Total Debt

Net Debt